Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 56 Guangzhou 46 Shanghai 28 Wuhan 26 Changsha 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital271 Beijing Tiantan Hospital219 Cancer Institute and Hospital, Chinese Academy of Medical Sciences205 AstraZeneca191 Peking University People's Hospital166 Clear sponsor filter
Site location
Beijing56 Guangzhou46 Shanghai28 Wuhan26 Changsha22
All 65 locations
Target enrolment
to

Trials with a site in Beijing

56 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Pfizer
Phase 3
432
Hefei, Beijing, Huizhou, Zhengzhou, Nanjing, Nanchang
2026-10-28
Active, closed
Pfizer
Phase 1
11
Beijing
2026-10-13
Recruiting
Pfizer
Phase 3
300
Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang
2026-09-24
Recruiting
Pfizer
Phase 3
336
Beijing, Shanghai
2026-07-30
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai, Hangzhou
2026-07-02
Recruiting
Pfizer
Phase 2
120
Beijing, Guangzhou, Jinan, Shanghai
2026-06-30
Recruiting
Pfizer
Phase 1/2
132
Beijing, Nanjing, Tianjin, Ningbo
2026-03-11
Recruiting
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Chongqing, Guangzhou, Huizhou, Xinxiang
2026-02-11
Recruiting
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Taizhou
2026-01-30
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-12-11
Recruiting
Pfizer
Phase 3
450
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
Pfizer
Phase 2
165
Fuzhou, Guangzhou, Shanghai, Beijing
2025-11-20
Recruiting
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Recruiting
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Recruiting
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
Pfizer
Phase 3
140
Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou
2025-09-10
Recruiting
Pfizer
Phase 3
400
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Wuhan
2025-08-05
Active, closed
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Recruiting
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Recruiting
Pfizer
Phase 2
620
Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an
2025-06-19
Recruiting
Pfizer
Phase 2
252
Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang
2025-05-20
Recruiting
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
Pfizer
Phase 3
723
Beijing, Chongqing, Shijiazhuang, Nanjing, Suzhou, Xi'an, Xianyang, Shanghai
2025-03-11
Recruiting
Pfizer
Phase 3
211
Hefei, Nanchang, Shanghai, Kunming, Beijing
2025-01-22
Active, closed
Pfizer
Phase 3
1,035
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Harbin, Wuhan
2025-01-06
Recruiting
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Active, closed
Pfizer
Phase 3
636
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Active, closed
Pfizer
Phase 3
609
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Active, closed
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Active, closed
Pfizer
Phase 3
1,571
Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha
2023-11-08
Recruiting
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
Active, closed
Pfizer
Phase 2
507
Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanchang
2023-08-22
Active, closed
Pfizer
Phase 3
59
Beijing, Guangzhou, Wuhan, Xi'an
2023-08-09
Recruiting
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Recruiting
Pfizer
Phase 2
48
Beijing, Guangzhou, Shanghai
2023-04-18
Active, closed
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Recruiting
Pfizer
Phase 3
100
Beijing, Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin
2022-12-09
Recruiting
Pfizer
Phase 3
1,060
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
DrugCrizotinib
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Recruiting
Pfizer
Phase 3
245
Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing
2021-11-17
Recruiting
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Active, closed
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Recruiting
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Active, closed
Pfizer
Phase 3
841
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing
2020-12-21
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole
Pfizer
Phase 2
320
Beijing, Guangzhou, Changchun, Xi'an
2020-11-16
Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
DrugAtirmociclib
Pfizer
Phase 1/2
430
Beijing, Zhengzhou, Wuhan, Xi’an, Hangzhou
2020-09-23
Active, closed
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Active, closed
Pfizer
Phase 3
1,054
Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong
2017-12-18
Active, closed
Pfizer
Phase 3
296
Beijing, Changchun, Shanghai, Hangzhou, Guangzhou
2017-04-27
Rows per page Showing 1–56 of 56
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 56 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

38 of the 56 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 56 studies
PhaseStudiesRecruitingShare
Phase 3352362.5%
Phase 210817.9%
Phase 1/2447.1%
Phase 4315.4%
Phase 2/3223.6%
Observational101.8%
Phase 1101.8%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Pfizer5638
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.